Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
AssigneeIN Ingredients, Inc.
InventorsAugustin T. Romero, Bolin Qin
Life of this patent
Estimating the term…
Abstract
Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of an active ingredient by weight. The active ingredient includes cinnamtannin D1 and/or cinnamtannin B1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein in the subject by the step of administering.
Claims16
A process of decreasing expression of a CD274 gene or a PD-L1 protein in a glial tumor cell in a subject comprising:
- administering to the subject 1-3 times daily for a period of 6 weeks or more a composition comprising cinnamtannin D1 and/or cinnamtannin B1, the glial tumor cell expressing a CD274 gene or a PD-L1 protein;
- wherein
- the cinnamtannin D1 and/or cinnamtannin B1 are at a concentration within said composition sufficient to decrease expression of the CD274 gene or the PD-L1 protein in said glial tumor cell;
- whereby said administration decreases the expression of the CD274 gene or the PD-L1 protein in said glial tumor cell.
A process of decreasing expression of a CD274 gene or a PD-L1 protein in a glial tumor cell expressing a CD274 gene or a PD-L1 protein in a subject comprising:
- administering to the subject a composition comprising cinnamtannin D1 and/or cinnamtannin B1;
- wherein the cinnamtannin D1 and/or cinnamtannin B1 are at a concentration within said composition sufficient to decrease expression of the CD274 gene or the PD-L1 protein in said glial tumor cell by said step of administering.
A process of treating a subject having a tumor that expresses a CD274 gene or a PD-L1 protein in a tumor expressing a CD274 gene or a PD-L1 protein comprising:
- administering to the subject a composition comprising cinnamtannin D1 and/or cinnamtannin B1;
- wherein the cinnamtannin D1 and/or cinnamtannin B1 are at a concentration within said composition sufficient to decrease expression of the CD274 gene or the PD-L1 protein in said tumor by said step of administering.
Dependencies are inferred from the claim text.